Vaccination and heterologous immunity: educating the immune system
- PMID: 25573110
- PMCID: PMC4351360
- DOI: 10.1093/trstmh/tru198
Vaccination and heterologous immunity: educating the immune system
Abstract
This review discusses three inter-related topics: (1) the immaturity of the neonatal and infant immune response; (2) heterologous immunity, where prior infection history with unrelated pathogens alters disease outcome resulting in either enhanced protective immunity or increased immunopathology to new infections, and (3) epidemiological human vaccine studies that demonstrate vaccines can have beneficial or detrimental effects on subsequent unrelated infections. The results from the epidemiological and heterologous immunity studies suggest that the immune system has tremendous plasticity and that each new infection or vaccine that an individual is exposed to during a lifetime will potentially alter the dynamics of their immune system. It also suggests that each new infection or vaccine that an infant receives is not only perturbing the immune system but is educating the immune system and laying down the foundation for all subsequent responses. This leads to the question, is there an optimum way to educate the immune system? Should this be taken into consideration in our vaccination protocols?
Keywords: Crossreactive; Heterologous immunity; Neonatal; T cells; Vaccines.
© The Author 2015. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Trained immunity: consequences for the heterologous effects of BCG vaccination.Trans R Soc Trop Med Hyg. 2015 Jan;109(1):29-35. doi: 10.1093/trstmh/tru168. Trans R Soc Trop Med Hyg. 2015. PMID: 25573107 Review.
-
Virus-Induced T Cell-Mediated Heterologous Immunity and Vaccine Development.Front Immunol. 2020 Mar 31;11:513. doi: 10.3389/fimmu.2020.00513. eCollection 2020. Front Immunol. 2020. PMID: 32296430 Free PMC article. Review.
-
The two faces of heterologous immunity: protection or immunopathology.J Leukoc Biol. 2014 Mar;95(3):405-16. doi: 10.1189/jlb.0713386. Epub 2013 Nov 8. J Leukoc Biol. 2014. PMID: 24212098 Free PMC article. Review.
-
The impact of vaccines on heterologous adaptive immunity.Clin Microbiol Infect. 2019 Dec;25(12):1484-1493. doi: 10.1016/j.cmi.2019.02.016. Epub 2019 Feb 20. Clin Microbiol Infect. 2019. PMID: 30797062 Review.
-
The expanding realm of heterologous immunity: friend or foe?Cell Microbiol. 2006 Feb;8(2):185-96. doi: 10.1111/j.1462-5822.2005.00653.x. Cell Microbiol. 2006. PMID: 16441430 Review.
Cited by
-
Overcoming immune dysfunction in the elderly: trained immunity as a novel approach.Int Immunol. 2020 Nov 23;32(12):741-753. doi: 10.1093/intimm/dxaa052. Int Immunol. 2020. PMID: 32766848 Free PMC article. Review.
-
The Regulation of Inflammation by Innate and Adaptive Lymphocytes.J Immunol Res. 2018 Jun 11;2018:1467538. doi: 10.1155/2018/1467538. eCollection 2018. J Immunol Res. 2018. PMID: 29992170 Free PMC article. Review.
-
Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia.Vaccines (Basel). 2020 Dec 1;8(4):719. doi: 10.3390/vaccines8040719. Vaccines (Basel). 2020. PMID: 33271962 Free PMC article.
-
Why Does the Severity of COVID-19 Differ With Age?: Understanding the Mechanisms Underlying the Age Gradient in Outcome Following SARS-CoV-2 Infection.Pediatr Infect Dis J. 2022 Feb 1;41(2):e36-e45. doi: 10.1097/INF.0000000000003413. Pediatr Infect Dis J. 2022. PMID: 34966142 Free PMC article. Review.
-
Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates.Front Immunol. 2024 May 10;15:1387454. doi: 10.3389/fimmu.2024.1387454. eCollection 2024. Front Immunol. 2024. PMID: 38799468 Free PMC article.
References
-
- Benn CS, Netea MG, Selin LK, Aaby P. A small jab - a big effect: nonspecific immunomodulation by vaccines. Trends Immunol. 2013;34:431–9. - PubMed
-
- Krishnan S, Craven M, Welliver RC, et al. Differences in participation of innate and adaptive immunity to respiratory syncytial virus in adults and neonates. J Infect Dis. 2003;188:433–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AI081675/AI/NIAID NIH HHS/United States
- R01 AI054455/AI/NIAID NIH HHS/United States
- R01 AI046578/AI/NIAID NIH HHS/United States
- P01 AI049320/AI/NIAID NIH HHS/United States
- AI-046578/AI/NIAID NIH HHS/United States
- AI-081675/AI/NIAID NIH HHS/United States
- T32-007349/PHS HHS/United States
- AI-054455/AI/NIAID NIH HHS/United States
- U19 AI109858/AI/NIAID NIH HHS/United States
- P01 AI046629/AI/NIAID NIH HHS/United States
- AI-046629/AI/NIAID NIH HHS/United States
- U19AI-109858/AI/NIAID NIH HHS/United States
- T32 AI007349/AI/NIAID NIH HHS/United States
- AI-049320/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
